tbuckley/cabot-search huggingface dataset:
IMPS-14PROGNOSTIC ROLE OF REGULATORY T-CELLS IN PRIMARY AND RECURRENT MENINGIOMA
Authors: Christel Herold-Mende, Theresa Ull, Carmen Rapp, Steffen Dettling, Christin Jungk, Felix Sahm, Andreas von Deimling, Andreas Unterberg, Matthias Simon
Journal: Neuro-Oncology (2015)

Although aggressive meningiomas WHO II and III are rare tumors, more effective therapies are urgently needed as reflected by a 5-year-recurrence rate of 50-80% in WHO III meningiomas. In the present study we aimed to learn more about the immunological situation of meningioma and thus a potential suitability of immunotherapeutic approaches. Occurrence of tumor-infiltrating lymphocytes (TILs) was studied in 114 primary and recurrent meningiomas WHO°I – III and quantified by multicolor immunofluorescence stainings using the markers CD3, CD8, and FOXP3 by using the semi-automated analysis method TissueFAXS. Although similar levels of TILs (CD3+) were found in all WHO grades, TIL numbers were higher in primary as compared to recurrent meningiomas. Phenotypic subclassification into effector and regulatory T-cells revealed elevated levels of T helper cells (CD8−) but not cytotoxic T-cells (CD8+). In contrast to effector T-cells, we found a significant increase of regulatory (FOXP3+) T-cells, which is mainly based on the CD8+ Treg cell phenotype. In contrast to all other T-cell phenotypes analyzed, solely FOXP3+ and in particular the CD8+ Treg cell subpopulation were increasing when comparing primary and recurrent meningioma and were further found to be correlated with a poor overall survival. Moreover, detection of Treg cells in primary meningioma is more frequently in patients developing recurrent tumors and might therefore serve as a negative prognostic marker. Furthermore, microarray analyses hint to profound changes in the tumor microenvironment with increasing WHO grade and recurrent tumors. Altogether, our results suggest a higher impact of quality than quantity of TILs, highlighting the importance of the microenvironment on the functional immune status, which needs to be considered for developing novel therapy approaches.
Identification of a Novel IL7RA Mutation (444_450insA) Caused Marked Reduction in CD127 Expression from a Cohort Molecular Analysis of Severe Combined Immunodeficiency (T−, B+, NK+ SCID) in Thailand.
Authors: Vip Viprakasit, Yuwarat Monteerarat, Orathai Piboonpocanun, Kleebsabai Sanpakit, Worrawut Chinchang, Kalaya Tachavanich, Nualanong Visitsunthorn, Visith Thongboonkerd, Prakit Vichyanond
Journal: Blood (2006)
Electronic Cigarette Use and Respiratory Symptoms in Adolescents
Authors: Rob McConnell, Jessica L. Barrington-Trimis, Kejia Wang, Robert Urman, Hanna Hong, Jennifer Unger, Jonathan Samet, Adam Leventhal, Kiros Berhane
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Rates of adolescent electronic (e-) cigarette use are increasing, but there has been little study of the chronic effects of use. Components of e-cigarette aerosol have known pulmonary toxicity.To investigate the associations of e-cigarette use with chronic bronchitis symptoms and wheeze in an adolescent population.Associations of self-reported use of e-cigarettes with chronic bronchitic symptoms (chronic cough, phlegm, or bronchitis) and of wheeze in the previous 12 months were examined in 2,086 Southern California Children's Health Study participants completing questionnaires in 11th and 12th grade in 2014.Ever e-cigarette use was reported by 502 (24.0%), of whom 201 (9.6%) used e-cigarettes during the last 30 days (current users). Risk of bronchitic symptoms was increased by almost twofold among past users (odds ratio [OR], 1.85; 95% confidence interval [CI], 1.37-2.49), compared with never-users, and by 2.02-fold (95% CI, 1.42-2.88) among current users. Risk increased with frequency of current use (OR, 1.66; 95% CI, 1.02-2.68) for 1-2 days and 2.52 (95% CI, 1.56-4.08) for 3 or more days in past 30 days compared with never-users. Associations were attenuated by adjustment for lifetime number of cigarettes smoked and secondhand smoke exposure. However, risk of bronchitic symptoms among past e-cigarette users remained elevated after adjustment for relevant potential confounders and was also observed among never-cigarette users (OR, 1.70; 95% CI, 1.11-2.59). There were no statistically significant associations of e-cigarette use with wheeze after adjustment for cigarette use.Adolescent e-cigarette users had increased rates of chronic bronchitic symptoms. Further investigation is needed to determine the long-term effects of e-cigarettes on respiratory health.
Role of CD133 As a Marker of Previous Myelodysplasia in De Novo Elderly Patients with Acute Myeloid Leukemia
Authors: Massimo Breccia, Maria Stefania De Propris, Mariella D'Angiò, Caterina Stefanizzi, Sara Raponi, Roberto Latagliata, Francesca Mancini, Anna Maria Testi, Saveria Capria, Silvia Maria Trisolini, Clara Minotti, Marta Chisini, Daniela Diverio, Teresa Ceglie, Marco Mancini, Federico Vozella, Gioia Colafigli, Adriano Salaroli, Anna Guarini, Robin Foà
Journal: Blood (2014)
Posttransplant Secondary Neoplasms: A Single Center Experience
Authors: Selin Berk, Dilek Keskin, Nurgul Ozgur Yurttas, Sevil Sadri, Isil Erdogan, Firat Yalniz, Tugrul Elverdi, Ayse Salihoglu, Ahmet Emre Eskazan, M. Cem Ar, Seniz Ongoren, Zafer Baslar, Nukhet Tuzuner, Yildiz Aydin, Teoman Soysal
Journal: Blood (2015)
Absence of T-Cell Receptor Gene Rearrangements Predicts Induction Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia.
Authors: Alejandro Gutierrez, Ruta Grebliunaite, Suzanne E. Dahlberg, Donna Neuberg, Jianhua Zhang, Takaomi Sanda, Alexei Protopopov, Lynda Chin, Stuart Winter, Richard S. Larson, Jeffery Lorne Kutok, Lewis B. Silverman, Stephen P Hunger, Stephen E. Sallan, A. Thomas Look
Journal: Blood (2009)
Multicenter randomized study of Gemcitabine and Oxaliplatin (GEMOX) +/- Panitumumab as First Line Treatment in K-Ras Wild type Advanced Biliary Tract Cancer; the VECTI-BIL study
Authors: D. Marino, R. Filippi, S. Cereda, C. Belli, R. Spadi, G. Nasti, M. Montano, A. Amatu, S.E. Lutrino, C. Cagnazzo, L. Ferrari, S. Siena, L. Ciuffreda, M. Reni, M. Aglietta, F. Leone
Journal: Annals of Oncology (2015)
Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) Sustains the Response Obtained After First-Line Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM).
Authors: Francesc Bosch, Neus Villamor, Pau Abrisqueta, María José Terol, Eva González-Barca, Marcos González, Christelle Ferrà, Eugenia Abella, Julio Delgado, Jose A Garcia-Marco, Yolanda Gonzalez, Felix Carbonell, Secundino Ferrer, Encarna Monzo, Isidro Jarque, Ana Muntanola, Mireia Constants, Lourdes Escoda, Emili Montserrat
Journal: Blood (2010)
Authors’ reply to Eisenhut
Authors: Saul Faust, Norma O’Flynn, Caroline Keir, Martin Allaby
Journal: BMJ (2016)

NICE guideline 51 covers the identification, risk assessment, and immediate management of people with suspected sepsis.1 It was not commissioned to replace other NICE guidance of specific conditions or to be a textbook of infectious diseases. In the absence of definitive biomarkers to diagnose sepsis, and in the face of many non-specific symptoms, the NICE guideline provides a pragmatic approach, recognising that at any stage other conditions may be diagnosed and more appropriate management pathways followed.

Eisenhut describes three …
EMA/CO for High-Risk Gestational Trophoblastic Tumors
Authors: M. Bower, E.S. Newlands, L. Holden, D. Short, C. Brock, G.J.S. Rustin, R.H.J. Begent, K.D. Bagshawe
Journal: Journal of Clinical Oncology (1997)

In the July 1997 article by Bower et al entitled, "EMA/CO for High-Risk Gestational Trophoblastic Tumors: Results From a Cohort of 272 Patients" (J Clin Oncol 15:2636–2643, 1997) there was an error in the abstract. The second sentence of the Results section of the abstract should have read: "No deaths from GTT have occurred later than 2 years after the end of EMA/CO."
P0390 : Baseline bilirubin and not Child-Pugh a or B7 predicts survival of BCLC B patients treated with sorafenib. The clinical approach to the stratification debate
Authors: A. Gazzola, R. Di Donato, M. Reig, N. Llarch, A. Forner, A. Darnell, J. Rimola, C. Ayuso, J. Bruix
Journal: Journal of Hepatology (2015)
Data Desert for Inferior Vena Caval Filters
Authors: Behnood Bikdeli, Joseph S. Ross, Harlan M. Krumholz
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
A Novel Method to Study the in Vivo Trafficking and Homing of Adoptively Transferred NK Cells in Rhesus Macaques and Humans
Authors: Jan Davidson-Moncada, Noriko Sato, Robert F Hoyt, Robert N Reger, Marvin Thomas, Randy Clevenger, Mark E. Metzger, Robert E. Donahue, Philip C Eclarinal, Lawrence Szajek, Gary L Griffiths, Cynthia E. Dunbar, Peter Choyke, Richard Childs
Journal: Blood (2014)
Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia : Single-Center Experience
Authors: Hwa Jung Sung, Eui Bae Kim, Se Ryeon Lee, Hee Yun Seo, Kyong Hwa Park, In keun Choi, Sang Chul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim
Journal: Blood (2008)
Shall we blame CD4 T cells for everything?
Authors: Tim F Greten, Firouzeh Korangy
Journal: Gut (2016)

Persistent inflammatory conditions in the liver promote chronic liver damage and liver fibrosis ultimately leading to hepatocellular carcinoma (HCC). Multiple cytokines have been investigated in the context of acute and chronic liver damage. Interleukin 17 (IL-17) is a proinflammatory cytokine produced by a subset of CD4 T cells (T helper 17 (Th17) cells). IL-17 recruits other immune cells such as monocytes and neutrophils to the site of inflammation in response to invasion by pathogens. It can promote inflammation and has been linked to various autoimmune disorders.1 In the liver, Th17 responses have been shown in non-alcoholic steatohepatitis, cholestatic liver diseases, liver fibrosis and antimicrobial defences.2 In this issue, Nadine Kuttkat from the Trautwein group investigated Th17 cells in a murine model of liver injury and HCC development.3 Following a previous report on the role of nuclear factor-kappa B (NF-κB) signalling events in hepatocytes using liver parenchymal cell-specific Nemo knockout (NemoLPC-KO or NemoΔHep) mice that develop steatohepatitis followed …
The Tyrosine Kinase Inhibitor TK258 Differentially Targets Proliferating Human Hematopoietic Progenitor Cells but Does Not Eliminate the Quiescent Fraction.
Authors: Caroline Alvares, Ian Titley, Mel Greaves, Michael Potter, Lyndal Kearney, Gareth Morgan, Kerol Bartolovic
Journal: Blood (2007)
Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma
Authors: Dan L. Longo, Vincent T. DeVita, Patricia L. Duffey, Margaret N. Wesley, Daniel C. Ihde, Susan M. Hubbard, Mercedes Gilliom, Elaine S. Jaffe, Jeffrey Cossman, Richard I. Fisher, Robert C. Young
Journal: Journal of Clinical Oncology (1991)

Table of the report entitled "Superiority of ProMACE-CytaBOM Over ProMACE-MOPP in the Treatment of Advanced Diffuse Aggressive Lymphoma: Results of a Prospective Randomized Trial" by Longo et al (J Clin Oncol 9:25–38, 1991) contained several errors. It is reprinted here correctly in its entirety: Please see the PDF for Table.
Vasectomy and risk of prostate cancer: population based matched cohort study
Authors: Madhur Nayan, Robert J Hamilton, Erin M Macdonald, Qing Li, Muhammad M Mamdani, Craig C Earle, Girish S Kulkarni, Keith A Jarvi, David N Juurlink
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To determine the association between vasectomy and prostate cancer, adjusting for measures of health seeking behaviour. <b>Design</b>&nbsp;Population based matched cohort study. <b>Setting</b>&nbsp;Multiple validated healthcare databases in Ontario, Canada, 1994-2012. <b>Participants</b>&nbsp;326 607 men aged 20 to 65 who had undergone vasectomy were identified through physician billing codes and matched 1:1 on age (within two years), year of cohort entry, comorbidity score, and geographical region to men who did not undergo a vasectomy. <b>Main outcomes measures</b>&nbsp;The primary outcome was incident prostate cancer. Secondary outcomes were prostate cancer related grade, stage, and mortality. <b>Results</b>&nbsp;3462 incident cases of prostate cancer were identified after a median follow-up of 10.9 years: 1843 (53.2%) in the vasectomy group and 1619 (46.8%) in the non-vasectomy group. In unadjusted analysis, vasectomy was associated with a slightly increased risk of incident prostate cancer (hazard ratio 1.13, 95% confidence interval 1.05 to 1.20). After adjustment for measures of health seeking behaviour, however, no association remained (adjusted hazard ratio 1.02, 95% confidence interval 0.95 to 1.09). Moreover, no association was found between vasectomy and high grade prostate cancer (adjusted odds ratio 1.05, 95% confidence interval 0.67 to 1.66), advanced stage prostate cancer (adjusted odds ratio 1.04, 0.81 to 1.34), or mortality (adjusted hazard ratio 1.06, 0.60 to 1.85). <b>Conclusion</b>&nbsp;The findings do not support an independent association between vasectomy and prostate cancer.
Flow Cytometry Study of CD148, a Tyrosine Phosphatase Receptor, in 184 Chronic B Cell Malignancies, Reveals a High Expression in Mantle Cell and Marginal Zone Lymphomas.
Authors: Laurent Miguet, Luc-Matthieu Fornecker, Estelle Zink, Guillaume Bechade, Raoul Herbrecht, Alain van Dorsselaer, Sarah Sanglier, Laurent Mauvieux
Journal: Blood (2009)
Imatinib Mesylate Has a Stage-Specific Inhibitory Role in Generation of CD26highCD8+ Central Memory T Cells in Vitro and in Vivo.
Authors: Kazuaki Yokoyama, Tokiko Nagamura-Inoue, Shin Nakayama, Ikuo Ishige, Kazuo Ogami, Munenori Futami, Seiichirou Kobayashi, Arinobu Tojo
Journal: Blood (2008)
Secondary Acute Myeloid Leukemia Is an Heterogeneous Subgroup of Elderly AML Where Patient’s Fitness Criteria and ELN Prognostic Stratification Can be Applied to Guide Treatment Decisions: An Analysis of 127 Patients By the Network Rete Ematologica Lombarda (REL)
Authors: Erika Borlenghi, Chiara Pagani, Claudia Basilico, Massimo Bernardi, Matteo Carrabba, Nicola Fracchiolla, Francesca Guidotti, Laura Marbello, Andrea Ferrario, Silvia Ferrari, Francesca Schieppati, Daniela Dalceggio, Giuseppe Rossi
Journal: Blood (2014)
Prostaglandin E2 promotes hepatic bile acid synthesis by an E prostanoid receptor 3‐mediated hepatocyte nuclear receptor 4α/cholesterol 7α‐hydroxylase pathway in mice
Authors: Shuai Yan, Juan Tang, Yuyao Zhang, Yuanyang Wang, Shengkai Zuo, Yujun Shen, Qianqian Zhang, Di Chen, Yu Yu, Kai Wang, Sheng‐Zhong Duan, Ying Yu
Journal: Hepatology (2016)

Prostaglandin E 2 (PGE 2 ) is an important lipid mediator of inflammation. However, whether and how PGE 2 regulates hepatic cholesterol metabolism remains unknown. We found that expression of the PGE 2 receptor, E prostanoid receptor 3 (EP3) expression is remarkably increased in hepatocytes in response to hyperlipidemic stress. Hepatocyte‐specific deletion of EP3 receptor ( EP3 hep–/– ) results in hypercholesterolemia and augments diet‐induced atherosclerosis in low‐density lipoprotein receptor knockout ( Ldlr –/– ) mice. Cholesterol 7α‐hydroxylase (CYP7A1) is down‐regulated in livers of EP3hep–/–Ldlr−/− mice, leading to suppressed hepatic bile acid (BA) biosynthesis. Mechanistically, hepatic‐EP3 deficiency suppresses CYP7A1 expression by elevating protein kinase A (PKA)‐dependent Ser143 phosphorylation of hepatocyte nuclear receptor 4α (HNF4α). Disruption of the PKA‐HNF4α interaction and BA sequestration rescue impaired BA excretion and ameliorated atherosclerosis in EP3hep–/–Ldlr−/− mice. Conclusion : Our results demonstrated an unexpected role of proinflammatory mediator PGE 2 in improving hepatic cholesterol metabolism through activation of the EP3‐mediated PKA/HNF4α/CYP7A1 pathway, indicating that inhibition of this pathway may be a novel therapeutic strategy for dyslipidemia and atherosclerosis. (H epatology 2017;65:999‐1014)
Endoscopic resection of high-risk T1 colorectal carcinoma prior to surgical resection has no adverse effect on long-term outcomes
Authors: A Overwater, K Kessels, S G Elias, Y Backes, B W M Spanier, T C J Seerden, H J M Pullens, W H de Vos tot Nederveen Cappel, A van den Blink, G J A Offerhaus, J van Bergeijk, M Kerkhof, J M J Geesing, J N Groen, N van Lelyveld, F ter Borg, F Wolfhagen, P D Siersema, M M Lacle, L M G Moons
Journal: Gut (2016)

It is difficult to predict the presence of histological risk factors for lymph node metastasis (LNM) before endoscopic treatment of T1 colorectal cancer (CRC). Therefore, endoscopic therapy is propagated to obtain adequate histological staging. We examined whether secondary surgery following endoscopic resection of high-risk T1 CRC does not have a negative effect on patients' outcomes compared with primary surgery. Patients with T1 CRC with one or more histological risk factors for LNM (high risk) and treated with primary or secondary surgery between 2000 and 2014 in 13 hospitals were identified in the Netherlands Cancer Registry. Additional data were collected from hospital records, endoscopy, radiology and pathology reports. A propensity score analysis was performed using inverse probability weighting (IPW) to correct for confounding by indication. 602 patients were eligible for analysis (263 primary; 339 secondary surgery). Overall, 34 recurrences were observed (5.6%). After adjusting with IPW, no differences were observed between primary and secondary surgery for the presence of LNM (OR 0.97; 95% CI 0.49 to 1.93; p=0.940) and recurrence during follow-up (HR 0.97; 95% CI 0.41 to 2.34; p=0.954). Further adjusting for lymphovascular invasion, depth of invasion and number of retrieved lymph nodes did not alter this outcome. Our data do not support an increased risk of LNM or recurrence after secondary surgery compared with primary surgery. Therefore, an attempt for an en-bloc resection of a possible T1 CRC without evident signs of deep invasion seems justified in order to prevent surgery of low-risk T1 CRC in a significant proportion of patients.
BCR-ABL P-Loop Deletion Detected in Imatinib-Resistant CML Patients Corresponds to Splice Variant Associated with L248V Point Mutation, Retains BCR-ABL Kinase Activity, and Responds to Dasatinib Treatment.
Authors: Nikolas von Bubnoff, Philipp Erben, Martin Müller, Tanja Lahaye, Susanne Schnittger, Frank Schlegel, Hubert Serve, Andreas Grüneisen, Rudiger Hehlmann, Christian Peschel, Justus Duyster, Andreas Hochhaus
Journal: Blood (2006)
Molecular Responses with Ponatinib in Patients with Philadelphia Chromosome Positive (Ph+) Leukemia: Results From the PACE Trial
Authors: Andreas Hochhaus, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C Muller, Carlo Gambacorti-Passerini, Stephane Wong, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G Haluska, Francois Guilhot, Michael W. Deininger, Timothy P. Hughes, John M Goldman, Neil Shah, Hagop M. Kantarjian, Jorge E. Cortes
Journal: Blood (2012)
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack
Authors: Yuesong Pan, Weiqi Chen, Yun Xu, Xingyang Yi, Yan Han, Qingwu Yang, Xin Li, Li’an Huang, S. Claiborne Johnston, Xingquan Zhao, Liping Liu, Qi Zhang, Guangyao Wang, Yongjun Wang, Yilong Wang
Journal: Circulation (2016)

Background: The association of genetic polymorphisms and clopidogrel efficacy in patients with ischemic stroke or transient ischemic attack (TIA) remains controversial. We performed a systematic review and meta-analysis to assess the association between genetic polymorphisms, especially CYP2C19 genotype, and clopidogrel efficacy for ischemic stroke or TIA. Methods: We conducted a comprehensive search of PubMed and EMBASE from their inceptions to June 24, 2016. Studies that reported clopidogrel-treated patients with stroke or TIA and with information on genetic polymorphisms were included. The end points were stroke, composite vascular events, and any bleeding. Results: Among 15 studies of 4762 patients with stroke or TIA treated with clopidogrel, carriers of CYP2C19 loss-of-function alleles (*2, *3, and *8) were at increased risk of stroke in comparison with noncarriers (12.0% versus 5.8%; risk ratio, 1.92, 95% confidence interval, 1.57–2.35; P &lt;0.001). Composite vascular events were also more frequent in carriers of CYP2C19 loss-of-function alleles than in noncarriers (13.7% versus 9.4%; risk ratio, 1.51, 95% confidence interval, 1.10–2.06; P =0.01), whereas bleeding rates were similar (2.4% versus 3.1%; risk ratio, 0.89, 95% confidence interval, 0.58–1.35; P =0.59). There was no evidence of statistical heterogeneity among the included studies for stroke, but there was for composite vascular events. Genetic variants other than CYP2C19 were not associated with clinical outcomes, with the exception that significant associations of PON1 , P2Y12 , and COX-1 with outcomes were observed in 1 study. Conclusions: Carriers of CYP2C19 loss-of-function alleles are at greater risk of stroke and composite vascular events than noncarriers among patients with ischemic stroke or TIA treated with clopidogrel.
Genome-Wide DNA Methylation Analysis Reveals Epigenetic Deregulation of Key Biological Pathways in Therapy-Related Myeloid Neoplasms
Authors: Orsolya Lautner-Csorba, Jason Sotzen, Fabiani Emiliano, Fianchi Luana, Stefan Hohaus, Giuseppe Leone, Maria Teresa Voso, Maria E Figueroa
Journal: Blood (2014)